Search Results

The i-STAT BNP test is an in vitro diagnostic test for the quantitative measurement of B-Type Natriuretic Peptide (BNP) in whole blood or plasma samples using EDTA as the anticoagulant. BNP measurements can be used as an aid in the diagnosis and assessment of the severity of congestive heart failure.

The cartridge is to be used with the i-STAT 1 Analyzer bearing the (Immuno) symbol, but not with the i-STAT Portable Clinical Analyzer or the Philips Medical Systems (formerly Agilent Technologies) Blood Analysis Module (BAM). As part of the i-STAT System, the BNP test is to be used by trained health care professionals in accordance with a facility's policies and procedures.

The i-STAT BNP Controls are assayed liquid plasma used to verify the integrity of newly received i-STAT BNP cartridges.

The i-STAT BNP Calibration Verification Controls are assayed liquid plasma used to verify the calibration of i-STAT BNP cartridges throughout the reportable range.

The i-STAT BNP test is contained in a single-use test cartridge. In use, the user scans a bar code and then places approximately 17 uL of whole blood or plasma in the cartridge. After the cartridge is closed, it is inserted into the thermally controlled i-STAT 1 Analyzer, and all analytical steps are performed automatically. Patient and use information may be entered into the analyzer via a keypad during the automated analysis cycle.

As the analyzer performs several quality checks and controls the temperature of the sensors via resistive heating to the underside of the sensor chips, the substrate/wash fluid is released into a conduit within the cartridge and a metered volume of the sample over the sensor chips. The enzyme-linked antibody conjugate dissolves into the sample incubates for a controlled time. The sample is then pushed into a waste chamber and the substrate/wash solution is brought over the sensors. The alkaline phosphatase captured on the BNP sensor cleaves the substrate present in the substrate/wash fluid, giving rise to an amperometric signal that is measured.

The i-STAT BNP Controls are supplied in three levels packaged as six vials of one level per box with each vial containing 1 mL of control material. The three levels are in frozen liquid form, require no reconstitution or dilution, and are each comprised of a different level of BNP, a chemical synthetic peptide, prepared in human EDTA plasma and preserved with sodium azide. The first level of BNP is set at a typical diagnostic cutoff level while the second and third are set at higher levels spanning the range of the test. The BNP value will be provided in the value assignment sheet for each level.

The i-STAT BNP Calibration Verification Control Set is packaged as a tri-level set comprised of two vials of each of three levels per box. The three levels in the BNP Calibration Verification Control Set are exactly the same materials as those used in the Level 1, Level 2, and Level 3 control products. The only difference between this product and the i-STAT BNP Controls is the number of vials and the number of levels that are packaged together.

The provided 510(k) summary focuses on the i-STAT BNP Test and its associated controls, asserting its substantial equivalence to a predicate device, the Biosite Triage BNP test. This document describes an immunoassay, not an AI-powered device, so several of the requested categories (e.g., number of experts, adjudication method, MRMC study, training set) are not applicable. I will provide information for the relevant categories based on the provided text.

1. Table of Acceptance Criteria and Reported Device Performance

For an immunoassay like the i-STAT BNP test, "acceptance criteria" are typically demonstrated through various performance characteristics compared to a predicate device or established analytical standards. The study demonstrates the clinical performance through a method comparison study, establishing correlation with a reference method.

Ask a specific question about this device

The i-STAT CHEM8+ Cartridge is intended to be used by medical professionals for the quantitative measurement of sodium, potassium, chloride, ionized calcium, glucose, urea nitrogen, total carbon dioxide, creatinine, and hematocrit in arterial, venous, and capillary blood. The i-STAT CHEM8+ Cartridge is useful for monitoring a variety of conditions. The panel of tests is used to assess kidney function, the hydration state, and blood sugar level. This test panel is also used to assess hypertension and hypokalemia.

The modified device is the i-STAT CHEM8+ Cartridge. The modifications comprise a combination of several tests, all of which are on the market and reside in other i-STAT cartridges, into a new panel of tests. The new i-STAT CHEM8+ Cartridge contains a panel comprised of nine reported tests and two calculated tests as is indicated on the labeling for this device. Of these nine reported test, eight tests (glucose, ionized calcium, sodium, potassium, chloride, carbon dioxide, urea nitrogen and creatinine) are commonly referred to as a "basic metabolic panel". The two tests to be reported as calculated parameters are anion gap and hemoglobin. The i-STAT CHEM8+ Cartridge is a single-use device that is to be used with the i-STAT 1 Analyzer. As with other i-STAT Cartridges, two or three drops of venous, arterial or capillary blood is dispensed into the cartridge, the blood are sealed inside the cartridge with the snap closure, and the cartridge is then inserted into the analyzer. The analysis cycle is automatic and is controlled by software in the analyzer. Cartridges are calibrated at the factory. This cartridge is similar in design to the other i-STAT cartridges that are used for the same or similar in vitro diagnostic tests. The i-STAT CHEM8+ Cartridge is manufactured using the same process technology and equipment that is used for existing i-STAT cartridges.

The provided text is a 510(k) summary for the i-STAT CHEM8+ Cartridge, which is a medical device intended for quantitative measurement of various metabolic parameters in blood. The document describes the device, its intended use, and its substantial equivalence to previously cleared devices. However, it does not contain the detailed study information, acceptance criteria, or performance data that would allow for a complete answer to the request. The summary states: "Hazards were identified and the associated risk was evaluated; all unacceptable risks were controlled to an acceptable level by design features and/or labeling. Users needs in the form of design inputs were defined and served as the basis for a design validation." This indicates that validation studies were performed, but the results and specifics are not provided in this excerpt.

Therefore, I cannot fully answer the request with the given input. I will highlight what information is not present in the document.

Here's an attempt to answer based on the provided text, indicating where information is missing:

Acceptance Criteria and Device Performance Study for i-STAT CHEM8+ Cartridge

The provided 510(k) summary for the i-STAT CHEM8+ Cartridge demonstrates substantial equivalence to existing i-STAT devices. The document implies that design validation was performed to ensure the device meets user needs and controls identified risks. However, specific acceptance criteria and detailed performance data from a study proving these criteria are met are not provided in this summary.

The summary states, "The performance of the tests contained in the modified (i-STAT CHEM8+) device and in the existing devices are equivalent for all diagnostic purposes." This suggests that performance studies were conducted to show equivalence, but the actual data, acceptance criteria, and study methodology are absent.

1. Table of Acceptance Criteria and Reported Device Performance

This information is not provided in the given 510(k) summary. The document does not list specific numerical acceptance criteria (e.g., accuracy, precision, bias limits) for each analyte, nor does it present a table of the reported performance results against such criteria.

2. Sample Size Used for the Test Set and Data Provenance

This information is not provided in the given 510(k) summary. Details such as the number of samples, their origin (e.g., country), and whether the data was retrospective or prospective are absent.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

This information is not provided in the given 510(k) summary. For in vitro diagnostic devices like the i-STAT CHEM8+ Cartridge, ground truth is typically established by reference laboratory methods, not usually by medical experts in the same way it would be for imaging interpretation. However, the document does not specify the method for establishing ground truth or the involvement of experts.

4. Adjudication Method for the Test Set

This information is not provided in the given 510(k) summary. Adjudication methods are typically relevant for studies involving human interpretation or subjective assessments, which is generally not the primary method for establishing ground truth for quantitative laboratory tests.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

A multi-reader multi-case (MRMC) comparative effectiveness study is not applicable to this device. The i-STAT CHEM8+ Cartridge is an in vitro diagnostic device for quantitative chemical analysis, not an imaging device requiring human interpretation. Therefore, a study comparing human readers with and without AI assistance is not relevant here.

6. Standalone Performance Study

The 510(k) summary implies that a standalone performance study was conducted to establish the equivalence of the i-STAT CHEM8+ Cartridge to existing predicate devices. It states: "The performance of the tests contained in the modified (i-STAT CHEM8+) device and in the existing devices are equivalent for all diagnostic purposes." This suggests that the algorithm (cartridge and analyzer) performance was assessed independently. However, the specific details, methodology, and results of such a standalone study are not included in this document.

7. Type of Ground Truth Used

For in vitro diagnostic devices like the i-STAT CHEM8+ Cartridge, the ground truth is typically established using reference laboratory methods (e.g., validated laboratory analyzers, mass spectrometry, or other established analytical techniques) rather than expert consensus, pathology, or outcomes data. However, the specific type of ground truth used for the studies is not explicitly stated in the provided summary.

8. Sample Size for the Training Set

This information is not provided in the given 510(k) summary. The i-STAT CHEM8+ Cartridge is an in vitro diagnostic device that uses established electrochemical sensor technology; the concept of a "training set" in the context of machine learning for image analysis or predictive algorithms typically does not directly apply here. The device's calibration is factory-set.

9. How the Ground Truth for the Training Set Was Established

As discussed above, the concept of a "training set" in the machine learning sense is generally not applicable to this type of device. The device's calibration is factory-set, and its performance is validated against reference methods. Details on calibration and validation methodologies are not provided in the summary.

Ask a specific question about this device

The i-STAT CK-MB test is an in vitro diagnostic test for the quantitative measurement of creatine kinase MB in whole blood or plasma samples. CK-MB measurements can be used as an aid in the diagnosis of myocardial infarction (MI).

The cartridge is to be used with the i-STAT 1 Analyzer bearing the (Immuno) symbol, but not with the i-STAT Portable Clinical Analyzer or the Philips Medical Systems (formerly Agilent Technologies) Blood Analysis Module (BAM). As part of the i-STAT System, the CK-MB test is to be used by trained health care professionals in accordance with a facility's policies and procedures.

The i-STAT Cardiac Troponin I (cTnl) test is an in vitro diagnostic test for the quantitative measurement of cardiac troponin I in whole blood or plasma. Measurements on cardiac troponin I are used as an aid in the diagnosis and treatment of patients with acute myocardial infarction and as an aid in the risk stratification of patients with acute coronary syndromes with respect to their relative risk of mortality.

The i-STAT CK-MB test is contained in a single-use test cartridge. In use, the user scans a bar code and then places approximately 16 uL of whole blood or plasma in the cartridge. After the cartridge is closed, it is inserted into the thermally controlled i-STAT 1 Analyzer, and all analytical steps are performed automatically. Patient and use information may be entered into the analyzer via a keypad during the automated analysis cycle.

As the analyzer performs several quality checks and controls the temperature of the sensors via resistive heating to the underside of the sensor chips, the substratelwash fluid is released into a conduit within the cartridge and a metered volume of the sample over the sensor chips. The enzyme-linked antibody conjugate dissolves into the sample and the sample incubates for a controlled time. The sample is then pushed into a waste chamber and the substrate/wash solution is brought over the sensors. The alkaline phosphatase captured on the CK-MB sensor cleaves the substrate present in the substrate/wash fluid, giving rise to an amperometric signal which is measured.

Here's an analysis of the provided text, focusing on the acceptance criteria and study information for the i-STAT CK-MB Test.

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria for substantial equivalence are not explicitly stated as numerical targets in the document. Instead, the general criteria are that the device should be "substantially equivalent" to the predicate device in terms of performance and safety. The reported device performance is compared to the predicate and to laboratory standards.

• Slope: 1.01
• Intercept: -0.19
• Correlation: 0.994
  **Samples where [CK-MB]

Ask a specific question about this device

The i-STAT Cardiac Markers Controls are an assayed liquid serum used to verify the integrity of newly received i-STAT cTnl cartridges.

The i-STAT Cardiac Markers Calibration Verification Controls are an assayed liquid serum used to verify the calibration of i-STAT cTnl cartridges throughout the reportable range.

The i-STAT Cardiac Markers Controls are supplied in three levels packaged as six vials of one level per box, with each vial containing 1 mL of control material. The three levels are each comprised of a different level of cardiac Troponin I, human creatinine kinase -- MB isoform CK-MB, and myoqlobin (all native forms) derived from human cardiac material, prepared in human serum, and preserved with sodium azide to inhibit microbial growth. The CK-MB and myoglobin are unassayed components in these materials. Only the cardiac troponin I (cTnl) values will be provided in the value assignment sheets for these products.

The Cardiac Markers Calibration Control Set is packaged as a tri-level set, comprised of two vials of each of three levels per box.

The acceptance criteria and study details for the i-STAT Cardiac Markers Control devices are described below.

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size and Data Provenance

• Test Set Sample Size: The document specifies "testing three lots of each control level" for the within-level vial imprecision study. The exact number of individual samples (vials) per lot is not provided.
• Data Provenance: Not explicitly stated, but given the context of a 510(k) submission, the data would typically be generated in-house by i-STAT Corporation (the manufacturer) in the United States, and would be prospective in nature, as it's a validation study for a new device.

3. Number of Experts and Qualifications

Not applicable. This device is a quality control material, not a diagnostic device requiring expert interpretation of images or patient data.

4. Adjudication Method

Not applicable for this type of device and study.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

Not applicable. This is a quality control material, not an AI-assisted diagnostic tool for human readers.

6. Standalone (Algorithm Only) Performance Study

Yes, a standalone study was performed. The data presented ("within-level vial imprecision" and "stability after thawing") represents the intrinsic performance of the control material itself, without human interpretation in the workflow.

7. Type of Ground Truth Used

The ground truth for this device is based on the inherent biochemical properties of the control material (cardiac Troponin I, CK-MB, and myoglobin), prepared in human serum, and preserved. The "assayed" components (cTnI) would have their values established through validated reference methods.

8. Sample Size for the Training Set

Not applicable. This device is a quality control material, not an AI algorithm that requires a training set. The performance studies are validation studies for the control material itself.

9. How the Ground Truth for the Training Set was Established

Not applicable, as there is no training set for this type of device. The "ground truth" for the control material's values (specifically for the assayed cTnI) would be established through a rigorous value assignment protocol using reference methods and multiple measurements, typically by the manufacturer.

Ask a specific question about this device

The i-STAT Kaolin Activated Clotting Time (ACT) test is an in vitro diagnostic test which uses fresh whole blood to monitor high-dose heparin anticoaqulation frequently associated with cardiovascular surgery. The test is to be used with the i-STAT Portable Clinical Analyzer (Models 200 and 300), but not the Philips Medical Systems (formerly Agilent Technologies) Blood Analysis Module (BAM). As part of the i-STAT System, the Kaolin ACT test is to be used by trained and certified health care professionals in accordance with a facility's policies and procedures.

The i-STAT Kaolin ACT test is contained in a single test cartridge. In use, approximately 40 microliters of fresh whole blood are placed in the cartridge is inserted into the thermally controlled i-STAT Model 200 or Model 300 Portable Clinical Analyzer, and all analytical steps are performed automatically. Patient and user information may be entered into the analyzer via a keypad during the automated analysis cycle. During the test the blood sample is mixed with reagents which are coated on the cartridge cover in a segment of the sensor channel. The reagent layer includes an activating agent, a thrombin substrate, and inert matrix components. These reagents allow activation of the coagulation cascade and detection of clot formation. In the i-STAT ACT test, the endpoint is indicated by the appearance of an electroactive marker generated by the thrombin-mediated conversion of a synthetic substrate included in the reagent. Detection of the marker indicates generation of thrombin and therefore complete activation of the coagulation cascade. The reported result is calculated from the time and rate of the substrate conversion and is given in seconds. The reported result correlates to the result of a traditional ACT in which the endpoint is indicated by physical clot formation.

The provided text describes the i-STAT Kaolin ACT test and its comparison to the predicate device, the Hemochron ACT test.

Here's an analysis of the acceptance criteria and the study that proves the device meets them:

1. A table of acceptance criteria and the reported device performance

The document doesn't explicitly state "acceptance criteria" with numerical targets for each performance metric. Instead, it presents the results of a comparison study against a predicate device and concludes that the i-STAT Kaolin ACT test shows "acceptable correlation" and "comparable" performance to the predicate. Based on the "Summary of Clinical Test Performance," we can infer the implied acceptance criteria were related to achieving a strong correlation and similar bias to the predicate device.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

• Sample Size:
  • Site 1: 311 patient samples
  • Site 2: 352 patient samples
  • Site 3: 313 patient samples
  • Total Clinical Samples: 976 patient samples
• Data Provenance: The studies were conducted at "three external sites" and used "samples taken during cardiovascular surgery procedures." This indicates a prospective collection of real-world patient samples. The document does not specify the country of origin, but given the submission is to the FDA (U.S.), it is highly probable the studies were conducted in the U.S.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This is not applicable as the "ground truth" for this device is a quantitative measurement (Activated Clotting Time), not an interpretation by experts. The comparison is against a predicate device, which itself measures ACT.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Not applicable. The study involves direct comparison of numerical results from two analytical devices, not subjective expert interpretations that would require adjudication.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This is not an AI-assisted diagnostic device, but an in vitro diagnostic test for measuring Activated Clotting Time. No human readers or AI assistance are involved in the measurement process.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Yes, the studies presented are effectively standalone performance studies for the i-STAT Kaolin ACT test. The device automatically performs the analysis once the blood sample is introduced into the cartridge and inserted into the analyzer. There is no human intervention in the result generation process itself, and the study compares the results generated by the i-STAT system directly against those of the predicate device.

7. The type of ground truth used (expert concensus, pathology, outcomes data, etc)

The "ground truth" in this context is the measurement provided by the predicate device, the Hemochron® Activated Whole Blood Clotting Time (Hemochron KACT). The study aimed to demonstrate that the i-STAT device's measurements are substantially equivalent to those of a legally marketed, established device.

8. The sample size for the training set

The document does not explicitly mention a "training set" for the device itself. Medical devices like this typically undergo a development and calibration phase, which involves extensive testing, but the term "training set" as understood in machine learning (where the algorithm learns from data) is not directly applicable here. The non-clinical studies (imprecision, linearity, sensitivity tests) represent development and validation data, but not a distinct "training set" in the AI sense.

9. How the ground truth for the training set was established

Not applicable (see point 8). For the non-clinical studies, "ground truth" would generally refer to known control values, known heparin concentrations, or comparison to established laboratory methods for determining fibrinogen levels, etc.

Ask a specific question about this device

The i-STAT cTnl test is an in vitro diagnostic test for the quantitative measurement of cardiac troponin I in heparinized whole blood or plasma samples. Cardiac troponin I measurements can be used as an aid in the diagnosis and treatment of myocardial infarction and in the risk stratification of patients with acute coronary syndromes with respect to their relative risk of mortality.

The cartridge is to be used with the i-STAT 1 Analyzer, but not with the i-STAT Portable Clinical Analyzer or the Philips Medical Systems (formerly Agilent Technologies) Blood Analysis Module (BAM). As part of the i-STAT System, the cTnl test is to be used by trained health care professionals in accordance with a facility's policies and procedures.

The i-STAT cTnl test is contained in a single test cartridge. In use, the user scans a barcode and then places approximately 16 microliters of fresh whole blood in the cartridge is inserted into the thermally controlled i-STAT 1 Analyzer, and all analytical steps are performed automatically. Patient and user information may be entered into the analyzer via a keypad during the automated analysis cycle.

As the analyzer performs several quality checks and controls the temperature of the sensors via resistive heating to the underside of the sensor chips, the substrate/wash fluid is released into a conduit within the cartridge and a metered volume of the sample over the sensor chips. The enzyme-linked antibody conjugate dissolves into the sample and the sample incubates for a controlled time. The sample is then pushed into a waste chamber and the substrate/wash solution is brought over the sensors. The alkaline phosphatase captured on the cTnl sensor cleaves the substrate present in the substrate/wash fluid, giving rise to an amperometric signal which is measured.

The cTnl test cartridge is assembled from plastic components that provide the conduits for fluid handling and house the sensor chips. The test is identified to the user through the name and color code on the cartridge label and by the analyzer through features integral to the cartridge.

Here's a breakdown of the acceptance criteria and study information for the i-STAT cTnI Test, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state formal "acceptance criteria" in a numerical or pass/fail format for clinical performance as might be seen for a new device. Instead, it demonstrates "substantial equivalence" to a predicate device. The performance metrics presented are comparative.

Ask a specific question about this device

The i-STAT PT is a prothrombin time test cartridge and is an in vitro diagnostic test intended for quantitative prothrombin time testing for the monitoring of oral anticoagulation therapy using fresh venous or capillary whole blood samples. The i-STAT PT test is not intended for evaluating individual factor deficiencies. The cartridge is to be used with the i-STAT Portable Clinical Analyzer with thermal control (Models 200 and 300), but will not run on the Philips Medical Systems (formerly Agilent Technologies) Blood Analysis Module (BAM). As part of the i-STAT System, the PT test is to be used by trained and certified health care professionals in accordance with a facility's policies and procedures.

The i-STAT PT, a prothrombin time test, is useful for monitoring patients receiving oral anticoagulation therapy such as Coumadin or warfarin.

The i-STAT PT test is contained in a single test cartridge. In use, approximately 40 microliters of fresh whole blood are placed in the cartridge as described below. The cartridge is inserted into the thermally controlled i-STAT Portable Clinical Analytical steps are performed automatically. Patient and user information may be entered into the analyzer via a keypad during the automated analysis cycle.

In the i-STAT PT test the endpoint is indicated by the appearance of an electroactive marker generated by the thrombin-mediated conversion of a synthetic substrate included in the reagent. Detection of the marker indicates generation of thrombin and therefore complete activation of the coagulation cascade. The result is reported as an International Normalized Ratio (INR) and, optionally, in seconds. The optionally displayed seconds is intended to reflect a typical plasma prothrombin time.

The PT test cartridge is assembled from plastic components that provide the conduits for fluid handling r no r r toot our negor chips. The coagulation test is identified to the user through the name and color code on the cartridge label and by the analyzer through features integral to the cartridge.

During the test the blood sample is mixed with reagents which are coated on the cartridge cover in a segment of the sensor channel. The reagent layer includes tissue thromboplastin as an activating agent, the thrombin substrate, a heparin-neutralizing enzyme, and inert matrix components. These reagents allow activation of the coagulation cascade and detection of clot formation.

Whole blood is introduced into the sample well of the cartridge at the sample port and the cartridge is closed and inserted into the analyzer. Insertion of the cartridge initiates a controlled and monitored sequence of steps in the instrument. These are:

• Electrical contact is made between the analyzer electronic input circuits and the cartridge. . The analyzer identifies the type of cartridge being used and the tests contained in the cartridge.
• The dry chips and sensor channel are heated to 37°C. .
• The blood is then moved forward. Feedback from the fluid position sensor is used to allow . controlled oscillation of the blood segment resulting in dissolution of the reagent layer.
• During the course of testing, the position of the blood segment is actively controlled to . maintain the length of the blood containing the reagent coincident with the endpoint detector.
• Calculation of the sample clot time is performed and displayed. .

The provided text describes the i-STAT PT Test, a prothrombin time test cartridge for monitoring oral anticoagulation therapy. The acceptance criteria and supporting studies are detailed in the "Summary of Non-Clinical Performance in Support of Substantial Equivalence" and "Summary of Clinical Test Performance is Support of Substantial Equivalence Claims" sections.

1. Table of Acceptance Criteria and Reported Device Performance:

The document doesn't explicitly state "acceptance criteria" in a quantitative, pass/fail manner. Instead, it demonstrates performance in various conditions and compares it to a predicate device, the Coaguchek™ S System. The implicit acceptance criteria appear to be the demonstrated insensitivity to certain factors and comparable performance to the predicate device within reasonable clinical limits.

2. Sample size used for the test set and the data provenance:

• Method Comparison Study (i-STAT PT vs. Dade Innovin lab instrument):
  • Sample Sizes: N = 183 (Site 1), N = 180 (Site 2), N = 177 (Site 3). Total = 540 patient samples.
  • Data Provenance: The samples were from "patients undergoing routine monitoring of oral anticoagulation therapy." This implies prospective clinical data collected at "three external sites." The country of origin is not explicitly stated but is implicitly the USA given the FDA submission.
• Capillary vs. Venous Sample Comparison Study:
  • Sample Size: N = 59.
  • Data Provenance: From "patients undergoing routine monitoring of oral anticoagulation therapy." This implies prospective clinical data from one site. The country of origin is not explicitly stated.
• Other non-clinical studies: The sample sizes for heparin-spiked, manipulated fibrinogen, and manipulated hematocrit samples are not specified, only that "studies established" these characteristics. These are likely laboratory-controlled, prospective studies.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

The ground truth for the clinical method comparison study was established by "laboratory plasma instruments using Dade Innovin reagent (x)". The document does not specify the number of experts or their qualifications for performing these reference laboratory tests. It's assumed to be standard clinical laboratory practice.

4. Adjudication method (e.g., 2+1, 3+1, none) for the test set:

No adjudication method is described. The comparison is directly between the i-STAT device and a reference laboratory method (Dade Innovin reagent) for patient samples, and between i-STAT capillary and venous samples.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

This is not an AI-assisted diagnostic device for human readers. It's an in vitro diagnostic (IVD) device. Therefore, an MRMC comparative effectiveness study involving human readers with/without AI assistance is not applicable and was not performed or described.

6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

The i-STAT PT test is a standalone device that automatically performs the test and reports results (INR and seconds). The analysis steps are "performed automatically." While "trained and certified health care professionals" use the device, their role is operational (sample collection, cartridge insertion, data entry), not interpretive in the sense of a diagnostic image or signal. The clinical studies described represent standalone performance of the device compared to a reference method.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

The primary ground truth for the device's performance claims against routine laboratory testing is comparison to a recognized laboratory reference method (Dade Innovin reagent on plasma instruments). For other claims (heparin, fibrinogen, hematocrit sensitivity), the ground truth was established through manipulated samples and clinical patient studies where the actual levels of these components could be measured and correlated with i-STAT results.

8. The sample size for the training set:

The document describes studies for validation and performance comparison for regulatory submission. It does not explicitly mention a separate "training set" for an algorithm. This suggests that if any internal algorithm development or calibration occurred, the data used for that is not disclosed here as a distinct training set. The clinical and non-clinical data presented are for demonstrating performance and substantial equivalence.

9. How the ground truth for the training set was established:

As no explicit "training set" is described for an algorithm, the method for establishing its ground truth is not applicable based on the provided text.

Ask a specific question about this device

The i-STAT System is used by trained medical professionals for running clinical chemistry tests for sodium, potassium, chloride, urea nitrogen, glucose, hematocrit, calcium, blood-gases (PCO2, PO2) and blood pH, creatinine, lactic acid, and activated whole blood clotting time in a variety of test panels contained in the i-STAT test cartridges.

The i-STAT System is used in conjunction with disposable i-STAT cartridges for determination of a variety of parameters in whole blood.

The provided text is a 510(k) summary for the i-STAT System, primarily focusing on a software modification to address interference in the PCO2 test. It does not contain a typical study design or acceptance criteria for a new device's performance directly. Instead, it references prior substantial equivalence determinations and focuses on the modification.

Therefore, many of the requested categories cannot be filled based on the provided document.

Here's an analysis of what information can be extracted or inferred, and what cannot:

1. Table of Acceptance Criteria and Reported Device Performance:

The document does not explicitly state acceptance criteria or a detailed performance table for this specific software modification. It mentions that the software modification was made "to diminish the interference on the PCO2 test caused by the drugs thiopental sodium and propofol." This implies that the previous performance in the presence of these drugs was unsatisfactory, and the modification aims to improve it, but no specific targets (e.g., % reduction in error, specific bias limits) are provided.

2. Sample Size Used for the Test Set and Data Provenance:

Not specified in the document.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Those Experts:

Not specified in the document.

4. Adjudication Method for the Test Set:

Not specified in the document.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done:

No. This device is a clinical analyzer, not an imaging device typically evaluated with MRMC studies comparing human readers.

6. If a Standalone (Algorithm Only Without Human-in-the-Loop Performance) Was Done:

The i-STAT System is a standalone clinical analyzer. The software modification described likely refers to an improvement in the algorithm that processes the PCO2 measurement from the sensor, without direct human-in-the-loop performance being a separate evaluation step. However, the document does not detail a specific standalone performance study for this modification. The device itself operates in a standalone manner.

7. The Type of Ground Truth Used:

Not specified in the document. For a clinical analyzer, ground truth would typically be established by a reference method (e.g., a laboratory-based blood gas analyzer) for the PCO2 measurement.

8. The Sample Size for the Training Set:

Not applicable/Not specified. This document describes a software modification to an existing device, not the training of a new AI model in the typical sense that would involve a "training set" with ground truth in the context of machine learning. The modification likely involved algorithm adjustments based on observed interference, rather than a large-scale machine learning training pipeline.

9. How the Ground Truth for the Training Set Was Established:

Not applicable/Not specified (as above).

Ask a specific question about this device

Ask a specific question about this device

Ask a specific question about this device